98 related articles for article (PubMed ID: 22975812)
41. Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Dhingra K; Talpaz M; Kantarjian H; Ku S; Rothberg J; Gutterman JU; Kurzrock R
Leukemia; 1991 Mar; 5(3):191-5. PubMed ID: 2013978
[TBL] [Abstract][Full Text] [Related]
42. Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.
Tsai SC; Shih LY; Liang ST; Huang YJ; Kuo MC; Huang CF; Shih YS; Lin TH; Chiu MC; Liang DC
Clin Cancer Res; 2015 Aug; 21(15):3541-51. PubMed ID: 25840971
[TBL] [Abstract][Full Text] [Related]
43. Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
Larsson N; Billström R; Lilljebjörn H; Lassen C; Richter J; Ekblom M; Fioretos T
Cancer Genet Cytogenet; 2010 Jun; 199(2):89-95. PubMed ID: 20471511
[TBL] [Abstract][Full Text] [Related]
44. Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Melo JV; Goldman JM
Leukemia; 1992 Aug; 6(8):786-90. PubMed ID: 1353550
[TBL] [Abstract][Full Text] [Related]
45. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
[TBL] [Abstract][Full Text] [Related]
46. Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?
Itzykson R; Fenaux P; Solary E
Best Pract Res Clin Haematol; 2013 Dec; 26(4):387-400. PubMed ID: 24507815
[TBL] [Abstract][Full Text] [Related]
47. Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology.
Karantanos T; Jain T; Moliterno AR; Jones RJ; DeZern AE
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807519
[TBL] [Abstract][Full Text] [Related]
48.
Tarrini G; Ciabatti E; Pacini S; Galimberti S; Petrini I
Anticancer Res; 2017 Oct; 37(10):5459-5462. PubMed ID: 28982856
[TBL] [Abstract][Full Text] [Related]
49. Risk of disease progression in low-risk MDS is linked to distinct epigenetic subtypes.
Qin T; Sotzen J; Rampal RK; Rapaport FT; Levine RL; Klimek V; Nimer SD; Figueroa ME
Leukemia; 2019 Nov; 33(11):2753-2757. PubMed ID: 31332268
[No Abstract] [Full Text] [Related]
50. p53 mutations indicate a changing clonal evolution in a portion of chronic myelocytic leukemia patients.
Guinn BA; Padua RA; Burnett A; Mills K
Blood; 1994 Nov; 84(10):3591. PubMed ID: 7949113
[No Abstract] [Full Text] [Related]
51. Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis.
Ohyashiki K; Ohyashiki JH
Cancer Genet Cytogenet; 1997 Mar; 94(1):67-72. PubMed ID: 9078293
[TBL] [Abstract][Full Text] [Related]
52. Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia.
Reap L; Goldman L
Leuk Res Rep; 2020; 14():100225. PubMed ID: 33134075
[TBL] [Abstract][Full Text] [Related]
53. ANKRD26-related thrombocytopenia and myeloid malignancies.
Noris P; Favier R; Alessi MC; Geddis AE; Kunishima S; Heller PG; Giordano P; Niederhoffer KY; Bussel JB; Podda GM; Vianelli N; Kersseboom R; Pecci A; Gnan C; Marconi C; Auvrignon A; Cohen W; Yu JC; Iguchi A; Miller Imahiyerobo A; Boehlen F; Ghalloussi D; De Rocco D; Magini P; Civaschi E; Biino G; Seri M; Savoia A; Balduini CL
Blood; 2013 Sep; 122(11):1987-9. PubMed ID: 24030261
[No Abstract] [Full Text] [Related]
54. Infrequent presentations of mucormycosis in patients with myelodysplastic syndrome and acute leukemia: case series and review of literature.
De Yao JT; Al-Ameri A; Garcia-Manero G; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):446-51. PubMed ID: 21820986
[No Abstract] [Full Text] [Related]
55. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.
Mossner M; Jann JC; Wittig J; Nolte F; Fey S; Nowak V; Obländer J; Pressler J; Palme I; Xanthopoulos C; Boch T; Metzgeroth G; Röhl H; Witt SH; Dukal H; Klein C; Schmitt S; Gelß P; Platzbecker U; Balaian E; Fabarius A; Blum H; Schulze TJ; Meggendorfer M; Haferlach C; Trumpp A; Hofmann WK; Medyouf H; Nowak D
Blood; 2016 Sep; 128(9):1246-59. PubMed ID: 27268087
[TBL] [Abstract][Full Text] [Related]
56. Resolution of a linguistic dilemma.
Janković GM
Blood; 1991 Jun; 77(12):2793-4. PubMed ID: 2043774
[No Abstract] [Full Text] [Related]
57. [Prominent leukemic infiltration in the lower gastrointestinal tract in a patient with chronic myelogenous leukemia (CML)].
Iida S; Nitta M; Nojiri O; Takeuchi G; Kodama H; Kohsaka K; Kamejima N; Takada K; Mitomo Y; Yamamoto M
Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):850-1. PubMed ID: 2794669
[No Abstract] [Full Text] [Related]
58. Understanding and utilizing new molecular genetics in MDS.
Figueroa ME
Clin Adv Hematol Oncol; 2013 Feb; 11(2):106-8. PubMed ID: 23598913
[No Abstract] [Full Text] [Related]
59. Leukemic pneumonitis in monocytic crisis of chronic myelogenous leukemia.
Yamauchi K; Nagao T; Yamazaki H
Am J Hematol; 1991 Aug; 37(4):286-7. PubMed ID: 1858791
[No Abstract] [Full Text] [Related]
60. Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).
Chang G; Meadows ME; Jones JA; Antin JH; Orav EJ
Am J Drug Alcohol Abuse; 2010 Jan; 36(1):1-6. PubMed ID: 20141389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
